Cardiovascular Consequences of Inhaled Short-acting Beta-agonist Use

Launched by UNIVERSITY OF ALBERTA · Sep 5, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how using asthma inhalers affects blood vessels and the heart in healthy young adults. Researchers want to find out if using these inhalers for a longer time can lead to any changes in cardiovascular health. To participate, individuals must be between 18 and 40 years old and in good health, without any history of heart or lung diseases. Participants will need to complete some lung function and exercise tests, have ultrasound images taken of their arm arteries, and use an inhaler for four weeks. They will visit the lab multiple times during the study.

During the trial, participants will be given either the inhalers Ventolin or Symbicort, or a placebo (a non-active treatment), to see if there are any differences in how these affect the blood vessels. It’s important to note that people with certain medical conditions, like heart issues or diabetes, or those who have used inhalants for more than a year, will not be eligible to take part. This study is currently recruiting participants, so if you fit the criteria and are interested, you could help researchers understand more about the impact of these inhalers on cardiovascular health.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Healthy participants between the ages of 18-40 years free from a medical history of cardiopulmonary disease
• Exclusion Criteria:
• • Absolute contraindication to exercise testing or an orthopedic condition that may limit exercise testing as identified by standardized health screening tool (PAR-Q+).
• • Abnormal findings during the pulmonary function test and/or cardiopulmonary exercise test including pulmonary function values below the lower limit of normal, decrease in FEV1 following exercise (\>10%), tachycardia (\>100bpm at rest), and resting hypertension (\>140/90 mmHg).
• • Pre-existing cardiac conditions (heart failure, congenital heart defect, valvular disease) that may limit exercise testing.
• • Comorbidities such as diabetes, dyslipidemia, liver disease, neuromuscular disease, renal disease, and respiratory disease
• • Prescription of medical inhaler
• • History of inhalants usage for greater than 1 year including but not limited to cigarettes, marijuana, and vaporizers.
• • Pregnancy or lactation
• • Women of childbearing potential must be willing to use an acceptable method of contraception to avoid pregnancy throughout the study. Acceptable methods of contraception include tubal ligation, oral contraceptive, and barrier methods. Abstinence is an acceptable form of contraception, only insofar as patients agree to use another acceptable method of birth control, preferably a barrier method, if they become sexually active.
• • Medication usage of monoamine oxidase inhibitors, tricyclic antidepressants, beta-blockers, diuretics, digoxin, other inhaled sympathomimetric bronchodilators or epinephrine, ritonavir, ketoconazole, itraconazole, cytochrome P450 sA4 inhibitors, xanthine derivatives, steroids, non-potassium sparing diuretics, L-Dopa, L-thyroxine, and oxytocin.